Skip to main content
رجوع
Watch Compare

Estrella Immunopharma, Inc.

جودة البيانات: 83%
مُدرج أيضًا باسم ESLAW Nasdaq
ESLA
Nasdaq Manufacturing Chemicals
KWD 1.83
▼ KWD 0.09 (-4.69%)
القيمة السوقية: 78.08 M
السعر
KWD 1.83
القيمة السوقية
78.08 M
نطاق اليوم
KWD 1.70 — KWD 1.97
نطاق 52 أسبوعًا
KWD 0.78 — KWD 3.15
حجم التداول
118,869
فتح KWD 1.97
متوسط 50 يوم / 200 يوم
KWD 1.15
58.76% above
متوسط 50 يوم / 200 يوم
KWD 1.32
38.80% above

Quick Summary

النقاط الرئيسية

Negative free cash flow of -1.79 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio0.15
Interest CoverageN/A

التقييم

PE (TTM)
-5.98
أقل من متوسط القطاع (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -6.0 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -13.06 M
ROE N/A ROA -401.70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1.79 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.15
Interest Coverage N/A Asset Turnover N/A
Working Capital -11.34 M Tangible Book Value -9.84 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5.98 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -2.29%
Market Cap 78.08 M Enterprise Value 76.45 M
Per Share
EPS (Diluted TTM) -0.35 Revenue / Share N/A
FCF / Share -0.04 OCF / Share -0.04
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 13.67%
SBC-Adj. FCF -2.26 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Revenue — — — —
Net Income -13.06 M -4.43 M -247,718.0 -996,104.0
EPS (Diluted) -0.35 -0.12 — —
Gross Profit — — — —
Operating Income -13.06 M -4.43 M -249,146.0 -1.57 M
EBITDA — — — —
R&D Expenses 10.25 M 2.86 M — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 838.0 63.0 0.0 80,648.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2021 FY2022
Total Assets 3.18 M 3.14 M 45.80 M 9.72 M
Total Liabilities 13.54 M 3.00 M 1.62 M 2.65 M
Shareholders' Equity -10.37 M 143,731.0 -1.01 M -2.26 M
Total Debt — — — —
Cash & Equivalents 1.38 M 916,916.0 478,868.0 40,802.0
Current Assets 1.68 M 1.64 M 616,034.0 52,427.0
Current Liabilities 13.54 M 3.00 M 73,154.0 1.07 M